Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | — |
Patient had been exposed to rabies on Friday, and only got the first dose of RabAvert on 12-Sep-2024; Case reference number US-BN-2024-002501 is a spontaneous case initially received from consumer via Med Communications (reference number USBAV24-2351) on 12-Sep-2024 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, reported as on Friday, the patient had rabies exposure. As reported, it was unknown if the animal had rabies. On 12-Sep-2024, unknown amount of time after rabies exposure, the patient received the first dose of RabAvert (batch number: unknown), at an unknown dose, route and site of administration, for rabies post-exposure prophylaxis (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A male patient of unspecified age received the first dose of RabAvert for rabies post-exposure prophylaxis on 12-Sep-2024, after the patient had rabies exposure, reported as on Friday, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age received the first dose of RabAvert for rabies post-exposure prophylaxis on 12-Sep-2024, after the patient had rabies exposure, reported as on Friday, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None